Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Skip to main content

Healthcare & Pharmaceuticals

Japan should have scrapped domestic trials to speed COVID shots - vaccine chief

2 minute read

A medical worker fills a syringe with a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine as Japan launches its inoculation campaign, at Tokyo Medical Center in Tokyo, Japan February 17, 2021. Behrouz Mehri/Pool via REUTERS/File Photo

TOKYO, June 15 (Reuters) - Japan's requirement of domestic clinical trials for COVID-19 vaccines cost it precious time in inoculating its population, vaccine programme chief Taro Kono said on Tuesday.

About 4.8% of the population has been fully vaccinated, a Reuters tracker shows, the lowest rate among large wealthy economies at a time when tens of thousands of visitors are poised to arrive for the Tokyo Olympics starting on July 23.

"If I could go back all the way to the beginning, I would have probably scrapped the clinical trial that we did," Kono told reporters.

"It's probably necessary for ordinary times, but in the case of emergency, or state of emergency, like COVID-19, I think we should have started the vaccination as early as possible."

Japan's mid-February start of vaccinations lagged most major economies and was dependent on initially scarce doses of Pfizer Inc's vaccine (PFE.N) imported from overseas.

Kono, the administrative reform minister tapped to head the programme in January, said opposition parties pushed for domestic trials and media would have pilloried the government if accidents had happened without them.

But some public health experts have said the domestic trials, involving 200 subjects or fewer, were scientifically meaningless.

In recent weeks, the vaccine campaign has picked up steam and is set to accelerate now that thousands of companies have signed up to use government supplies to administer shots to employees and families.

Kono said he hoped daily vaccinations would hit one million by the end of June, up from about 700,000 now.

Reporting by Rocky Swift; Editing by Andrew Heavens

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters